The future of TCR therapy appears promising, with ongoing research focused on improving its efficacy and safety. Advances in genetic engineering and bioinformatics are expected to enhance the ability to identify suitable antigens and customize TCRs for individual patients. Clinical trials are expanding to explore its application in various cancers, and combination therapies with other treatments, like checkpoint inhibitors, are being investigated to overcome resistance mechanisms.
